0 Commenti
0 condivisioni
388 Views
0 Anteprima
Cerca
Scopri nuove persone e i loro amici a quattro zampe, e fai nuove amicizie
-
Effettua l'accesso per mettere mi piace, condividere e commentare!
-
GLP-1 Receptor Agonists Obesity Drugs Market: Insights, Key Players, and Growth AnalysisAccording to the latest report published by Data Bridge Market Research, the GLP-1 Receptor Agonists Obesity Drugs Market CAGR Value The global GLP-1 receptor agonists obesity drugs market size was valued at USD 9.96 billion in 2024 and is expected to reach USD 33.12 billion by 2032, at a CAGR of 16.21% during the forecast period With the...0 Commenti 0 condivisioni 291 Views 0 Anteprima
-
GLP-1 Receptor Agonists Obesity Drugs Market: Insights, Key Players, and Growth AnalysisAccording to the latest report published by Data Bridge Market Research, the GLP-1 Receptor Agonists Obesity Drugs Market CAGR Value The global GLP-1 receptor agonists obesity drugs market size was valued at USD 9.96 billion in 2024 and is expected to reach USD 33.12 billion by 2032, at a CAGR of 16.21% during the forecast period This...0 Commenti 0 condivisioni 251 Views 0 Anteprima
-
GLP-1 Receptor Agonists Obesity Drugs Market: Insights, Key Players, and Growth AnalysisAccording to the latest report published by Data Bridge Market Research, the GLP-1 Receptor Agonists Obesity Drugs Market The global GLP-1 receptor agonists obesity drugs market size was valued at USD 9.96 billion in 2024 and is expected to reach USD 33.12 billion by 2032, at a CAGR of 16.21% during the forecast period CAGR Value With a...0 Commenti 0 condivisioni 312 Views 0 Anteprima
-
GLP-1 Market: Research Advancements and Industry DevelopmentsThe GLP-1 Market is expanding as therapeutic applications move beyond diabetes into obesity and cardiovascular disease. Valued at USD 52.82 billion in 2025, the GLP-1 Market is projected to reach USD 58.48 billion in 2026 and USD 133.92 billion by 2034, growing at a CAGR of 10.9% during the forecast period 2026–2034. Key players include AstraZeneca, Boehringer Ingelheim, D&D...0 Commenti 0 condivisioni 81 Views 0 Anteprima